Last reviewed · How we verify

NCT03224754

Atypia of Undetermined Significance (AUS) / Follicular Lesion of Undetermined Significance (FLUS)

Withdrawn Last updated 11 May 2018
What this trial tests

trial testing Determination of risk of malignancy of these thyroid lesions in Diagnoses Disease. Withdrawn.

Timeline
18 July 2017
Primary endpoint
2 May 2018
2 May 2018

Quick facts

Lead sponsorUniversity of Mississippi Medical Center
StatusWithdrawn
Study typeOBSERVATIONAL
Start date18 July 2017
Primary completion2 May 2018
Estimated completion2 May 2018
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Mississippi Medical Center

Who can join

Eligibility, any sex, with Diagnoses Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

According to the guidelines for reporting thyroid fine needle aspirations known as The Bethesda System, the category of atypical cells known as AUS/ FLUS category has an estimated rate of 5 to 15% for malignancy. This study aims to determine the rate of malignancy of this category in our institution and to evaluate the clinical outcome of the participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diagnoses Disease

Currently open trials in the same condition.

Other University of Mississippi Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03224754.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing